Thursday 14 October 2021
14:00 to 17:00 CET
TB detection, treatment, and care of individuals with TB continue to be a challenge, particularly in settings with a high burden of disease and weakened healthcare infrastructure. More recently, the COVID-19 pandemic has added complex layers of stress to health systems worldwide, hampering progress in the fight against TB. The Global Laboratory Initiative (GLI) and the Global Drug- Resistant TB Initiative (GDI) are working towards strengthening laboratory and clinical management capacity for the programmatic management of TB. Through this workshop, we will explore the challenges encountered in countries, and steer the discussion on how to address these as protect progress in the fight against TB.
Session sponsor: World Health Organization's Global TB Programme
Chairs: Dr. Elisa Tagliani, San Raffaele Scientific Institute; Dr. Sarabjit Singh Chadha, The Foundation For Innovative New Diagnostics
Coordinators: Medea Gegia (WHO); Cal-Michael Nathanson (WHO)
- Matteo Zigno, Who: WHO Guidelines on TB detection and DR-TB treatment: What is new and upcoming solutions
- Patricia J. Hall, CDC: Selecting setting-specific solutions for TB detection: A New GLI Tool
- Swapna Uplekar, FIND: Practical considerations for implementing next-generation sequencing in national TB programmes
- Brian Citro, Global Drug-Resistant TB Initiative: Legal & Policy Solutions to End DR-TB: An Assessment of 10 High Burden Countries' Fulfillment of UNHLM Legal Commitments
- Ignacio Monedero-Recuero, Global drug-resistant TB Initiative (GDI): Situation analysis of the ten high DR TB burden countries at two year from the UNHLM declaration: progress and setbacks in changing landscape
The recording of this session will be available to the public a few hours after it ends.